The U.K. cost-effectiveness standard for drugs will increase by 25% in exchange for zero tariffs on the country’s pharmaceutical exports. The new trade agreement’s parameters could shape deals the Trump administration is pursuing with other countries.
Nikkei Asian Review reported that the company would cover some or all the cost of the therapy, Alofisel, which won EMA approval last year, if it did not provide benefit. The UK's NICE has declined to recommend it, citing modest benefit in a clinical trial.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK's NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.
The decision is not final, but the Swiss drugmaker's shares were down 1 percent in morning trading. NICE reached a similar decision last month on competitor Gilead's Yescarta.
Negotiations with country-level reimbursement authorities will follow. The UK's NICE turned down Gilead's Yescarta Tuesday.
The PBM will incorporate cost-per-QALY analyses from ICER, but the program also drew some criticism.
Alan Murray on improving access for medical transportation.